VivoSeq
Oncology

Anatomic Stage I Breast Cancer AJCC V8

10

Pipeline Programs↗

6

Active Trials↗

9

Companies Involved↗

Anatomic Stage I Breast Cancer AJCC v8 is an early-stage landscape with 10 programs across 9 companies. The most active players are TerSera Therapeutics LLC, AbbVie, Merck & Co.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

22/100

Mech. Concentration

33/100

Completion Rate

0/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TerSera Therapeutics LLC

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2A

Avyxa

1 program

Phase 2Teva logo

Teva

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

8 of 11 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody327%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

8

clinical trials

Recruiting5 · 63%
Terminated1 · 13%
Active, not recruiting1 · 13%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

MC250301, OptiOFS: A Randomized Phase II Trial of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Breast Cancer
Recruiting·MMayo Clinic·Phase 2·NCT07460752·98 enrolled
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade
Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT06876714·1,524 enrolled
Examining the Feasibility of Implementing a Biobehavioral Stress Reduction Program in Triple Negative Breast Cancer Patients
Recruiting·OOhio State University Comprehensive Cancer Center·Preclinical·NCT05677802·40 enrolled
Optimization of Adjuvant Systemic Therapy in Patients With Early HER2-Positive (HER2+) Breast Cancer or Triple Negative Breast Cancer (TNBC) That Achieved a Pathological Complete Response (pCR) After Neoadjuvant Systemic Therapy and Do Not Have Molecular Residual Disease (MRD-Negative): A Phase II Clinical Trial (The MolecularPCR Trial)
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07407920·120 enrolled
Phase 2 Interventional Trial of Ovarian Function Suppression for Breast Cancer (OFS)
Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT07158021·75 enrolled
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Active, not recruiting·ECOG-ACRIN Cancer Research Group·Phase 2·NCT04001829·249 enrolled
A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04216472·6 enrolled
Evaluation of Circulating Tumor DNA Based Minimal Residual Disease Detection in Early Stage Breast Cancer Patients: A Prospective Study
Withdrawn·CCity of Hope Medical Center·Preclinical·NCT07136493

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)